
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company with two neuroscientific programs targeting a broad range of neurologic and neuropsychiatric disorders. Our novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain, anxiety, and cognitive decline, often associated with early-stage dementia. We have an exclusive licensing agreement for Ketamir-2 (“Ketamir”), a unique, patent-pending novel oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).
Up to 90% verified emails and mobile numbers, refreshed weekly.
MIRA Pharmaceuticals operates in the Biotechnology industry and is headquartered in United States.
MIRA Pharmaceuticals has approximately 2-10 employees employees.
MIRA Pharmaceuticals is based in Miami, Florida, United States.
Yes. MIRA Pharmaceuticals is a publicly traded company.
You can reach MIRA Pharmaceuticals’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.
Our team will be in touch soon. If you have any questions, please email us at info@scalelist.com
Just a few more details..
Our team will be in touch soon. If you have any questions, please email us at arnaud@scalelist.com